Literature DB >> 27666605

Predictive values of BI-RADS(®) magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS).

Gustavo Machado Badan1, Sebastião Piato2, Décio Roveda3, Eduardo de Faria Castro Fleury3.   

Abstract

PURPOSE: The purpose of this study was to evaluate BI-RADS indicators in the detection of DCIS by MRI.
MATERIALS AND METHODS: Prospective observational study that started in 2014 and lasted 24 months. A total of 110 consecutive patients were evaluated, who presented with suspicious or highly suspicious microcalcifications on screening mammography (BI-RADS categories 4 and 5) and underwent stereotactic-guided breast biopsy, having had an MRI scan performed prior to biopsy.
RESULTS: Altogether, 38 cases were characterized as positive for malignancy, of which 25 were DCIS and 13 were invasive ductal carcinoma cases. MRI had a sensitivity of 96%; specificity of 75.67%; positive predictive value (PPV) for DCIS detection of 57.14%; negative predictive value (NPV) in the detection of DCIS of 98.24%; and an accuracy of 80.80%.
CONCLUSION: BI-RADS as a tool for the detection of DCIS by MRI is a powerful instrument whose sensitivity was higher when compared to that observed for mammography in the literature. Likewise, the PPV obtained by MRI was higher than that observed in the present study for mammography, and the high NPV obtained on MRI scans can provide early evidence to discourage breast biopsy in selected cases.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biopsy; Breast; Breast neoplasms; Carcinoma; Intraductal; Large-core needle; Magnetic resonance imaging; Mammography; Noninfiltrating

Mesh:

Year:  2016        PMID: 27666605     DOI: 10.1016/j.ejrad.2016.07.010

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  1 in total

1.  Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients.

Authors:  Jianhua Fang; Yi Shao; Jiezhi Su; Ying Wan; Lingyun Bao; Wei Wang; Fanlei Kong
Journal:  Ther Clin Risk Manag       Date:  2018-08-28       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.